DNER and B-cell non-Hodgkin lymphoma: These results are highly significant as they add vital knowledge for clinical decisions regarding precision medicine strategies for using BET inhibitors as a single agent or in combination to treat patients with aggressive treatment refractory B-cell lymphomas.